Navidea biopharma announces full enrollment in ongoing phase 2b trial of tc99m tilmanocept

Navidea biopharmaceuticals announces full enrollment in its ongoing phase 2b trial of tc99m tilmanocept in rheumatoid arthritis (ra).navidea biopharmaceuticals - remains on track to meet with fda to finalize phase 3 study design, phase 2b trial to continue in parallel until completion.navidea biopharmaceuticals inc - nav3-31 phase 2b study is on track for last patient to be screened, and evaluated by end of 2020.
NAVB Ratings Summary
NAVB Quant Ranking